DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera.

IF 21 1区医学 Q1 HEMATOLOGY

Blood Pub Date : 2025-04-15 DOI:10.1182/blood.2024027528

Ghaith Abu-Zeinah,Katie Erdos,Neville Lee,Yara Ganom,Christoph Klade,Kurt Krejcy,Heinz Gisslinger,Richard T Silver,Joseph Michael Scandura

引用次数: 0

Abstract

DNMT3A mutations in polycythemia vera (PV) patients were heterogenous and not enriched in interferon-alpha (IFN)-treated patients. DNMT3A mutations had no detectable impact on hematologic response, molecular response or survival outcomes.

查看原文本刊更多论文

DNMT3A突变不太可能影响真性红细胞增多症患者的干扰素治疗结果。

真性红细胞增多症（PV）患者的DNMT3A突变是异质性的，并且在干扰素- α (IFN)治疗的患者中不富集。DNMT3A突变对血液反应、分子反应或生存结果没有可检测到的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood 医学-血液学

CiteScore

23.60

自引率

3.90%

发文量

955

审稿时长

1 months

期刊介绍： Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.